Oculis Holding: Promising Pipeline Developments and Strong Financial Position Support Buy Rating

Analyst Serge Belanger from Needham maintained a Buy rating on Oculis Holding and keeping the price target at $36.00.

Serge Belanger’s rating is based on several promising developments within Oculis Holding’s pipeline. The company has three programs in late-stage development, with particular emphasis on the phase 3 trials of OCS-01 in diabetic macular edema (DME), which are anticipated to yield results in the second quarter of 2026. These results are crucial as they are expected to support a New Drug Application (NDA) filing later that year, marking a significant milestone for the company.
Additionally, Oculis Holding’s financial position is robust, with a pro-forma cash reserve of $292 million following a recent equity raise. This financial strength is projected to sustain the company until 2029, providing a solid foundation for its ongoing and future projects. The combination of these factors, including the potential for transformational data from the upcoming trials, underpins Belanger’s Buy rating and the $36 price target for the stock.